Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Custirsen Combination Misses Goal in Phase III mCRPC Trial

April 28th 2014

The combination of custirsen (OGX-011) with docetaxel and prednisone failed to significantly extend survival as a first-line treatment for men with metastatic castration-resistant prostate cancer

Dr. Petrylak on Imaging Approaches in Prostate Cancer

April 25th 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer

Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPC

April 23rd 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Crawford Discusses Prostate Cancer Biopsies

April 22nd 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses prostate cancer biopsies.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.

Adding ADT to RT Reduces Risk of Progression in Localized Prostate Cancer

April 15th 2014

Patients with localized prostate cancer at intermediate or high risk for progression experience better outcomes when 6 months of androgen deprivation therapy is added to standard radiotherapy.

Pretreatment Genetic Test Predicts Recurrence in Prostate Cancer

April 14th 2014

A novel 100-locus DNA signature obtained from pretreatment biopsies accurately classified 75% of patients with untreated prostate cancer as low- or high-risk.

Dr. Dreicer on Next-Generation AR Therapies in CRPC

April 14th 2014

Robert Dreicer, MD, MS, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer.

Dr. Tagawa on CTCs in Neuroendocrine Prostate Cancer

April 11th 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the molecular characterization of circulating tumor cells (CTCs) in neuroendocrine-positive prostate cancer.

Dr. Petrylak on Novel Imaging Modalities in Prostate Cancer

April 9th 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses novel imaging modalities in prostate cancer.

Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD

April 8th 2014

An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.

Dr. Crawford on Predictive Tests in Prostate Cancer

April 4th 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses valuable prognostic and predictive tests to help urologists determine when to biopsy, when to rebiopsy, and how to direct treatment for patients with a positive biopsy.

Dr. Sartor on Provenge in Combination with Radium-223

April 1st 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses a trial that would study Provenge (sipuleucel-T) in combination with radium-223 as a potential treatment option for patients with prostate cancer.

Dr. Thompson on Prostate Biopsy Problems and Solutions

March 31st 2014

Ian M. Thompson, MD, director, professor, Department of Urology, Cancer Therapy & Research Center, The University of Texas Health Science Center, discusses the problems with prostate biopsies and some possible solutions.

Dr. Pelman on Determining Treatments for Newly Diagnosed Prostate Cancer

March 28th 2014

Richard S. Pelman, MD, president of the American Association of Clinical Urologists and an urologist at the University of Washington Department of Urology, discusses techniques for selecting patients for radical prostatectomy or watchful waiting and active surveillance.

Dr. Dreicer on Combining Agents With Immunotherapies

March 27th 2014

Robert Dreicer, MD, MS, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.

Dr. Petrylak on Custirsen in Prostate Cancer

March 24th 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses a phase III trial measuring the efficacy of custirsen plus docetaxel versus docetaxel alone in patients with prostate cancer (SYNERGY trial).

Dr. Oh on a Biomarker Development Trial in mCRPC

March 20th 2014

William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC).

Hospital Admissions and Rectal Procedures are More Common After Radiotherapy Than Prostatectomy

March 18th 2014

Men with clinically localized prostate cancer who were treated with radiotherapy were more likely, over the subsequent 5 years, to be admitted to a hospital, undergo rectal, anal, or open surgical procedures, or develop secondary malignancies than men treated with radical prostatectomy